Today we're joined by Ivan Kairatov, a biopharma expert with a deep understanding of the technological innovations driving the industry, particularly in oncology. His work at the intersection of research and development gives him a unique perspective on the recent FDA clearance for PharmaResearch’s
The ambitious journey of bringing a groundbreaking therapy from a laboratory concept to a patient-ready treatment is increasingly intersecting with the harsh realities of a complex and fragmented manufacturing landscape. As biopharmaceutical innovators pioneer increasingly sophisticated molecules,
The immense success of messenger RNA vaccines painted a tantalizing picture of a medical revolution, yet the very technology that made them possible has also been a barrier to their wider therapeutic use. While transformative in preventing infectious diseases, the first generation of mRNA delivery
Beijing Huaguan Biotechnology Co., Ltd., a pioneering force in synthetic biology and green chemical manufacturing, has officially closed its Series C financing round, securing hundreds of millions of RMB to accelerate its growth trajectory. This substantial capital infusion was driven by a
In a move that sends ripples across the global pharmaceutical landscape, AstraZeneca has committed to a landmark $15 billion investment in China, a strategic initiative designed to run through 2030. The announcement, made on January 29, 2026, signals a profound deepening of the company's research,
Researchers have developed a groundbreaking microfluidic chip using a single-step 3D printing process that successfully mimics the three-dimensional environments where cells grow in the human body, a development poised to revolutionize how diseases are studied and new drugs are tested. This new
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37